Category:

Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

States are seeking to try value-based payment models to mitigate high drug costs, but there are plenty of barriers to implementing these programs…Several states have rolled out outcomes-based or population-based models for drug pricing in Medicaid. Louisiana and Washington, for example, operate “Netflix-style” subscription models for hepatitis C drugs. States such as Michigan and Oklahoma are testing outcomes-based approaches...“This is just really new territory for a lot of these states to even interact with manufacturers this way—knowing just the right mechanisms and the right way to begin these conversations,”…there are few models to learn from, and taking lessons from one another can also be a challenge...READ MORE

It’s bad news for pharmaceutical company sales reps. U.S. physicians are increasingly too busy to see them…Given the common complaint that they don’t have enough time to spend with patients, busy doctors are making less time to meet with pharma representatives…As physicians increasingly struggle to balance their time with patient loads, electronic health records and time spent on administrative tasks, almost half of doctors don’t have time to meet in-person with pharma sales reps...seeing reps in-person dropped from 67% last year to 54% in this year’s survey...READ MORE

With Purdue Pharma agreeing to settle with dozens of cities and states for a record-setting $12 billion, more opioid settlements could be on the way. But Purdue's agreement doesn't mean all the defendants are willing to go to the negotiating table quietly…Defendants in a Cleveland multidistrict litigation have gone so far as to attack the judge in charge of the case. In a...motion, retailers and distributors—but no drugmakers—demanded the removal of Judge Dan Polster for pushing a settlement. The absence of a pharma company there could show opioid makers are looking for deals rather than continuing to spar it out...READ MORE

Big M&A has returned to pharma smack in the middle of a fierce drug pricing debate—and a group of senators is urging the Federal Trade Commission to weigh those deals accordingly...Of particular interest? AbbVie's proposed $63 billion Allergan buyout and Bristol-Myers Squibb's Celgene merger...M&A has been picking up across the economy...pharma included. And specifically in the drug industry, “consolidation is occurring against a backdrop of ever-rising prescription drug spending and reports that one in four people taking prescription drugs have difficulty affording their medication,” ...READ MORE

An independent expert panel to the U.S. Food and Drug Administration...recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray that aims to help smokers quit their addiction...The panel...saying its benefits as a smoking cessation aid outweighed risks. The FDA usually follows the recommendations of its experts, but is not mandated to do so...Panel members also raised concerns regarding the potential for abuse and misuse of the product by non-smokers and teenagers...READ MORE

Four people have been charged in a $99 million pharmacy fraud scheme...the defunct New York and New Jersey pharmacy group Prime Aid Pharmacies had been charged in a scheme that involved paying kickbacks to physicians and falsifying documents to fraudulently bill for medications that were not dispensed to patients...Prime Aid was able to secure network agreements with several pharmacy benefit managers that allowed it to earn reimbursements from both federal and private payers... Prime Aid also bribed physicians by paying an employee to work in the doctors' offices...the company received $65 million in reimbursements for drugs that they not only failed to provide to patients but that they never stocked or ordered...READ MORE

Walgreens is testing a new on-demand delivery service with Alphabet’s drone delivery service Wing, beginning next month...The pilot program will deliver food and beverage, over-the-counter medications and other items within minutes...Prescription deliveries will not be available...Walgreens will be the first retailer in the U.S. to test an on-demand drone delivery service...READ MORE

Fifty-eight people have been charged with engaging in healthcare fraud schemes that centered on the illegal distribution of more than 6 million opioid pills across Texas...Some 16 medical professionals, including six doctors and seven pharmacists, were charged in the schemes, which featured one pharmacy in Houston that illegally dispensed more than 760,000 pills from March 2018 to September 2019…The schemes in Texas entailed Medicare fraud that resulted in more than $66 million in losses...They also included $158 million in fraudulent claims for compound creams and $23 million in tax evasion...Federal authorities have frozen $60 million in assets of the people accused...READ MORE

Paying well is one way to lure job seekers in and keep existing talent happy, in biopharma and beyond. And while CEOs often catch the limelight for their multimillion-dollar paychecks…Here, we rank the top 10 most generous biopharma companies, ranked by median employee pay in 2018. You’ll notice that most of them have just one or a few products and number their employees in the hundreds or one or two thousand...Big Pharma companies may win in terms of size and revenues, but their median compensation is no match for that of these R&D-heavy biotechs. Take AbbVie, with a 30,000-strong team that looks like a traditional Big Pharma. Its median salary was $148,823 in 2018. That number was the highest among large multinationals including Johnson & Johnson, Pfizer, Merck & Co., Eli Lilly, Bristol-Myers Squibb and AbbVie's buyout target Allergan, but came nowhere near the median salary of $216,797 at Jazz—No. 10 on our list...READ MORE